WASHINGTON – A booster dose of the vaccine Pfizer against COVID-19 in children between the ages of five and 11 increased the level of antibodies, the pharmaceutical company confirmed on Thursday.
The additional dose, given six months after the first two doses, increased antibodies against the original strain of coronavirus six-fold.
The vaccine booster trials included 140 children aged five to 11 years. In a smaller analysis of 30 children in the trial, Pfizer said the extra dose increased the level of antibodies against the Omicron variant of the coronavirus by 36 percent.
This article was published in NBC News. To read it in full, Click here.
–
Related posts:
Learn about the precursors to diabetes to avoid getting sick
Palencia concludes that the future of cereals lies in adapting production to consumer needs | News
New Hope for Men with Prostate Cancer: Revolutionary Drug Treatment Shows Promising Results
sturdy in the appropriate put and at the suitable time
/data/photo/2022/04/12/62556c65268e5.jpg?resize=150%2C150&ssl=1 "Russia Threatens to Attack Command Center in Kyiv if Ukraine Continues")